Skip to main content
Premium Trial:

Request an Annual Quote

Highmark to Cover Biodesix's Veristrat Test

NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Highmark, a Blue Cross Blue Shield affiliate, for its Veristrat lung cancer test.

With the decision, Veristrat, which is intended to help guide second-line treatment in patients with advanced non-small cell lung cancer, gains access to Highmark's membership of 5.3 million people, the fourth-largest membership among BCBS-affiliated companies.

Veristrat uses MALDI mass spectrometry to measure plasma protein profiles of NSCLC patients with the aim of determining appropriate treatment for patients without epidermal growth factor receptor mutation or whose mutation status is unknown.

"Highmark's decision to cover VeriStrat enables a significantly larger patient population to benefit from the prognostic and predictive qualities of our proprietary test," Biodesix CEO David Brunel said in a statement.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.